Account
Watchlists
Bookmarks
Pricing
Market Cap
₹ 535 Cr
P/E
40.03
Investor Presentation
Q2 FY26
Investor Presentation
Q4 FY25
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Bearish
3
Neutral
8
Bullish
3
Bearish
14
Neutral
16
Bullish
16
Bearish
11
Neutral
8
Bullish
13
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1117.00 | 770 Cr | — | 2.33 | 0.09 | -1.63 | -0.95 | -4.66 | |
334.00 | 586 Cr | 21.27 | 2.21 | 0.00 | 10.38 | 11.71 | 6.55 | |
390.70 | 539 Cr | 50.38 | 1.96 | 0.24 | 3.88 | 4.69 | 2.31 | |
231.00 | 535 Cr | 40.03 | 6.36 | 0.00 | 0.00 | 0.00 | 15.55 | |
1090.00 | 487 Cr | 14.77 | 2.67 | 1.63 | 18.04 | 24.68 | 15.78 | |
335.00 | 404 Cr | — | 74.02 | 0.00 | -417.29 | -15.11 | -16.54 | |
149.00 | 352 Cr | 33.33 | 3.86 | 0.00 | 11.59 | 11.00 | 5.46 |
Influx Healthtech Limited is a contract development and manufacturing organization (CDMO) specializing in nutraceuticals, cosmetics, pet care, and homecare products.
The company reported a noteworthy 39% increase in revenue for H1 FY26, reaching INR 66.8 crores, driven mainly by its nutraceutical segment. Meanwhile, EBITDA rose by 61% during the same period.
Influx Healthtech plans strategic capacity expansion through IPO proceeds, targeting a 2.5x increase in capacity, which will significantly enhance their manufacturing capabilities across nutraceutical and veterinary divisions.
The company launched multiple new products across different categories, such as ayurvedic gummies and nutritional oral gels, reflecting a robust innovative pipeline and a focus on market trends.
Influx Healthtech has received several industry certifications, including GMP, NSF, and FDA approvals, which position it favorably for market expansion, particularly in export markets.
Pharmaceuticals
Pharmaceuticals - Indian - Formulations
535 Cr
Low Risk
40.0
43.8
2.0
6.4
249.00
120.00
Sales CAGR
1Y
4.88%
3Y
—
5Y
—
10Y
—
Profit CAGR
1Y
20.13%
3Y
—
5Y
—
10Y
—
ROE
TTM
—
3Y
44.90%
5Y
48.18%
10Y
—
ROCE
TTM
—
3Y
59.96%
5Y
63.92%
10Y
—
Performance
STEADY PERFORMER
Valuation
OVERVALUED
Growth
STABLE
Profitability
MODERATE MARGIN
Technicals
Bullish
Risk
MODERATE RISK
